Promising novel therapies for the treatment of endometrial cancer

Gynecologic Oncology

Volumn 116, Issue 2, 2010, Pages 187-194

  Gehrig, Paola A ^a   Bae Jump, Victoria L ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Biologic therapy; Chemotherapy; Endometrial cancer; Molecular targets; Novel therapeutics

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CYTOTOXIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FULVESTRANT; GEFITINIB; GEMCITABINE; IMATINIB; IXABEPILONE; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MAPATUMUMAB; MATUZUMAB; MONOCLONAL ANTIBODY; PACLITAXEL; PEMETREXED; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; TEMSIROLIMUS; TRASTUZUMAB;

CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; ENDOMETRIUM CANCER; GENE MUTATION; HUMAN; IN VITRO STUDY; MORBIDITY; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

CLINICAL TRIALS, PHASE II AS TOPIC; DRUG DELIVERY SYSTEMS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING;

EID: 74249119959     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.10.041     Document Type: Review

References (99)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., and Thun M.J. Cancer statistics 2009. CA Cancer J. Clin. 59 (2009) 225-249
2. Dunton C.J., Balsara G., Mcfarland M., and Hernandez E. Uterine papillary serous carcinoma: a review. Obstet. Gynecol. Surv. 46 (1991) 97-102
3. Homesley H.D., Filiaci V., Gibbons S.K., Long H.J., Cella D., Spirtos N.M., et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with our without paclitaxel: A Gynecologic Oncology Group study. Gynecol. Oncol. 112 (2009) 543-552
4. Randall M.E., Filiaci V.L., Muss H., Spirtos N.M., Mannel R.S., Fowler J., et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 24 (2006) 36-44
5. Fleming G.F., Brunetto V.L., Cella D., Look K.Y., Reid G.C., Munkarah A.R., et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastin in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 22 (2004) 2159-2166
6. Fleming G.F., Filiaci V.L., Bentley R.C., Herzog T., Sorosky J., Vaccarello L., et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann. Oncol. 15 (2004) 1173-1178
7. Thigpen J.T., Brady M.F., Homesley H.D., Malfetano J., DuBeshter B., Burger R.A., et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 22 (2004) 3902-3908
8. Gallion H.H., Brunetto V.L., Cibull M., Lentz S.S., Reid G., Soper J.T., et al. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 21 (2003) 3808-3813
9. Thigpen J.T., Blessing J.A., DiSaia P.J., Yordan E., Carson L.F., and Evers C.A. randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 12 (1994) 1408-1414
10. Cohen C.J., Bruckner H.W., Deppe G., Blessing J.A., Homesley H., and Lee J.H. Multidrug treatment of advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Obstet. Gynecol. 63 (1984) 719-726
11. Fleming G.F., Sill M.A., Thigpen J.T., et al. Phase II evaluation of trastuzumab in patients with advanced or recurrent endometrial carcinoma: a report on GOG 181B. Proc. Am. Soc. Clin. Oncol. 22 (2003) A-1821,453
12. McMeekin D.S., Sill M.W., Benbrook D., Darcy K.M., Stearns-Kurosawa D.J., Eaton L., et al. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Gynecol. Oncol. 105 (2007) 508-516
13. Leslie K.K., Sill M.W., Darcy K.M., Baron A.T., Wilken J.A., Godwin A.K., et al. Efficacy and safety of gefitinib and potential prognostic value of soluble EGFR, EGFR mutations, and tumor markers in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. J. Clin. Oncol. 27 (2009) abstr e16542
14. Aghajanian C., Sill M.W., Darcy K., Greer B., McMeekin D.S., Rose P.G., et al. A phase II evaluation of bevacizumab in the treatment of recurrent or persistent endometrial cancer. A Gynecologic Oncology Group study. J. Clin. Oncol. 27 (2009) 5531
15. Garcia A.A., Blessing J.A., Nolte S., and Mannel R.S. A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group. Gynecol. Oncol. 111 (2008) 22-26
16. Miller D.S., Blessing J.A., Kranser C.N., Drake R.D., Higgins R., McMeekin D.S., et al. A phase II evaluation of pemetrexed (Alimta, LY231514, INC#40061) in the treatment of recurrent or persistent endometrial carcinoma. A phase II study of the Gynecologic Oncology Group. J. Clin. Oncol. 27 (2009) abstract e16507
17. Dizon D.S., Blessing J.A., McMeekin D.S., Sharma S.k., Disilvestro P., and Alvarez R. Phase II trial of Ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic Oncology Group study. J. Clin. Oncol. 27 (2009) 3104-3108
18. Doll A., Abal M., Rigau M., Monge M., Gonzalez M., Demajo S., et al. Novel molecular profiles of endometrial cancer-new light through old windows. J. Steroid Biochem. Mol. Biol. 108 (2008) 221-229
19. Bokhman J.V. Two pathogenic types of endometrial carcinoma. Gynecol. Oncol. 15 (1983) 10-17
20. Hecht J, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 206;24:4783-91.
21. Mutter G.L., Lin M.C., Fitzgerald J.T., Kum J.B., Baak J.P., Lees J.A., et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J. Natl. Cancer Inst. 92 (2000) 924-930
22. Maxwell G.L., Risinger J.I., Gumbs C., Shaw H., Bentley R.C., Barrett J.C., et al. Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res. 58 (1998) 2500-2503
23. Basil J.B., Goodfellow P.J., Rader J.S., Mutch D.G., and Herzog T.J. Clinical significance of microsatellite instability in endometrial carcinoma. Cancer 89 (2000) 1758-1764
24. Bilbao C, Rodriguez G., Ramirez R., Falcon O., Leon L., Chirino R., et al. The relationship between microsatellite instability and PTEN gene mutations in endometrial cancer. Int. J. Cancer 119 (2006) 563-570
25. Lax S., Kendall B., Tashiro H., Slebos R.J., and Hedrick L. The frequency of p53,K-ras mutations and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 88 (2000) 814-824
26. Zheng W., Cao P., Zheng M., Kramer E.E., and Godwin T.A. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes. Gynecol. Oncol. 61 (1996) 167-172
27. Santin A.D., Bellone S., Gokden M., Palmieri M., Dunn D., Agha J., et al. Overexpression of Her-2/neu in uterine serous papillary cancer. Clin. Cancer Res. 8 (2002) 1271-1279
28. Slomovitz B.M., Broaddus R.R., Burke T.W., Sneige N., Soliman P.T., We W., et al. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J. Clin. Oncol. 22 (2004) 3126-3132
29. Risinger J.L., Maxwell G.L., Chandramouli G.V., Jazaeir A., Aprelikova O., Patterson T., et al. Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res. 63 (2003) 6-11
30. Zorn K.K., Bonome T., Gangi L., Chandramouli G.V., Awtrey C.S., Gardner G.J., et al. Gene expression profiles of serous, endometrioid and clear cell subtypes of ovarian and endometrial cancer. Clin. Cancer Res. 11 (2005) 6422-6430
31. McMeekin D.S., Filiaci V.L., Thigpen J.T., Gallion H.H., Fleming G.F., and Rodgers W.H. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. Gynecol. Oncol. 106 (2007) 16-22
32. Ellis LM, Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumor activity. Nat. Rev., Cancer 8 (2008) 579-591
33. Salvesen H.B., Iversen O.E., and Akslen L.A. Independent prognostic importance of microvessel density in endometrial cancer. Br. J. Cancer 77 (1998) 1140-1144
34. Mazurek A., Telego M., Pierzynski P., Lapuc G., Niklinska W., Juczewska M., et al. Angiogenesis in endometrial cancer. Neoplasma 45 (1998) 360-364
35. Hirai M., Nakagawara A., Oosaki T., Hayashi, Hirono M., and Yoshihara T. Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma. Gynecol. Oncol. 80 (2001) 181-188
36. Holland C.M., Day K., Evans A., and Smith S.K. Expression of the VEGF and angiopoietin genes in endometrial atypical hyperplasia and endometrial cancer. Br. J. Cancer 89 (2003) 891-898
37. Kamat A.A., Merritt W.M., Coffey D., Lin Y.G., Patel P.R., Broaddus R., et al. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin. Cancer Res. 13 (2007) 7487-7495
38. Lee C.N., Cheng W.F., Chen C.A., Chu J.S., Hsieh D.Y., and Hsieh F.J. Angiogenesis of endometrial carcinomas assessed by measurement of intratumoral blood flow, microvessel density, and vascular endothelial growth factor levels. Obstet. Gynecol. 96 (2000) 615-621
39. Yokoyama Y., Sato S., Futagami M., Fukushi Y., Sakamoto T., Umemoto M., et al. Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma. Gynecol. Oncol. 77 (2000) 413-418
40. Fine B.A., Valente P.T., Feinstein G.I., and Dey T. VEGF, flt-1 and KDR/flk-1 as prognostic indicators in endometrial carcinoma. Gynecol. Oncol. 76 (2000) 33-39
41. Talvensaari-Mattila A., Soini Y., and Santala M. VEGF and its receptors (flt-1 and KDR/flk-1) as prognostic indicators in endometrial carcinoma. Tumour Biol. 26 (2005) 81-87
42. Fujimoto J., Toyoki H., Jahan I., Alam S.M., Sakaguchi H., Sato E., et al. Sex-steroid-dependent angiogenesis in uterine endometrial cancers. Ster. Biochem. Mol. Biol. 93 (2005) 161-165
43. Columbo N., Mangilia G., Mammoliti S., Kalling M., Tholander B., Sternas L., et al. Afibercept (VEGF trap) for advanced epithelial ovarian cancer (EOC) patients with symptomatic malignant ascites: preliminary results of a pilot study. J. Clin. Oncol. 26 (2008) 14598
44. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathways and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64 (2004) 7099-7109
45. Nimeiri H., Oza A.M., Morgan R.J., Friberg G., Kasza K., Faora L., et al. Sorafenib in patients with advanced/recurrent uterine carcinoma or carcinosarcoma: a Phase II trial of the Chicago, PMH and California Phase II consortia. J. Clin. Oncol. 26 (2008) 5585 [2008 ASCO Annu Meet Proc]
46. Matei D., Sill M.W., DeGeest K., and Bristow R.E. Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group study. Proc. Am. Soc. Clin. Oncol. 26 (2008) 5537
47. Welch S., Hirte H., Schilder R.J., Elit L., Townsley C., Tinker L., et al. Phase II study of sorafenib (BAY 43-9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: a PMH phase II consortium trial. J. Clin. Oncol. 24 (2006) 5084
48. Fleming G.F., Morgan R., Wang L., Welch S., Mackay H.J., Hirte H., et al. A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: a trial of the PMH Phase II consortium. J. Clin. Oncol. 27 (2009) 5576 2009 ASCO Annu Meet Proc
49. Hirte H.W., Vidal L., Fleming G.F., Sugimoto A.K., Morgan R.J., Biagi J.J., et al. A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal, or fallopian tube cancer;final results of PMH, Chicago and California consortia trial. Proc. Am. Soc. Clin. Oncol. 26 (2008) 5521
50. Bhaskar V., Fox M., Breinberg D., Wong M.H., Wales P.E., Rhodes S., et al. Volociximab, a chimeric integrin α5β1 antibody inhibits the growth of VX2 tumors in rabbits. Invest. New Drugs 26 (2008) 7-12
51. Delmonte A., Del Conte G., Sessa C., Perotti A., Fasolo A., Williams E., et al. Results from a phase 1/2 study of volociximab in combination with liposomal doxorubicin in relapsed advanced epithelial ovarian and primary peritoneal carcinoma. Proc. Am. Soc. Clin. Oncol. 26 (2008) 16527
52. Vergote I.B., Colombo N., Kutarska E., Del Camp J., Pippitt C., Casado A., et al. Phase II study of comparing volociximab (an antiangiogenic antibody) and peglylated liposomal doxorubicin (PLD) with PLD alone in recurrent ovarian or primary peritoneal cancer. J. Clin. Oncol. 27 (2009) 5560
53. Camidge D.R., Eckhardt S.G., Diab S., Gore L., Chow L., O'Bryant C., et al. A phase I dose-escalation study of weekly IMC-1121B, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR2) IgG1 monoclonal antibody in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. 26 (2008) 16527
54. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307 (2005) 58-62
55. Wolf J., and Slomovitz B.M. Novel biologic therapies for the treatment of endometrial cancer. Int. J. Gynecol. Cancer 15 (2005) 411
56. Abraham R.T. Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr. Opin. Immunol. 10 (1998) 330-336
57. Oza A.M., Elit L., Biagni J., Chapman W., Tsao M., Hedley D., et al. Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer. J. Clin. Oncol. 24 (2006) 3003
58. Oza A.M., Elit L., Provencher D., et al. A Phase II study of temsirilimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy. J. Clin. Oncol. 26 (2008) 5516
59. Colombo N., McMeekin D.S., Schwartz P., Kostka, Sessa C., Gehrig P.A., et al. A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer. Proc. Am. Soc. Clin. Oncol. 25 (2007) 5516
60. Slomovitz BM, Burke T, Lu KH, Wolf J, Johnston T, Wu W, et al. Loss of PTEN expression associated with response to RAD001 (mTOR inhibitor) in patients with recurrent endometrial cancer: Translational evaluation from a phase II study. 2007;104:S30, abstract 70.
61. Bae-Jump V.L., Zhou C., Boggess J.F., and Gehrig P.A. Synergistic effect of rapamycin and cisplatin in endometrial cancer cells. Cancer 115 (2009) 3887-3896
62. Shafer A., Zhou C., Gehrig P.A., Boggess J.F., and Bae-Jump V.L. Rapamycin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and induction of apoptosis. AACR (2008) Accepted Int J Cancer
63. Mondesire W.H., Jian W., Zhang H., Ensor J., Hung M.C., Mills G.B., et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin. Cancer Res. 10 (2004) 7031-7042
64. Elser D., Hirte H., Kaizer L., MacKay H., Bindra S., Tinker L., et al. Phase II study of MKC-1 in patients with metastatic or resistant epithelial ovarian cancer or advanced endometrial cancer. J. Clin. Oncol. 27 (2009) 5577
65. Hrzenjak A., Kremser M.L., Storhmeier B., Moinfar F., Zatloukal K., and Denk H. SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway. J. Pathol. 216 (2008) 495-504
66. De Luca A., Carotenuto A., Rachiglio A., Gallo M., Maiello M.R., Aldinucci D., et al. The role of EGFR signaling in tumor microenvironment. J. Cell. Physiol. 214 (2008) 559-567
67. Niikura H., Sasano H., Kaga K., Sato S., and Yajima A. Expression of epidermal growth factor family proteins and epidermal growth factor receptor in human endometrium. Hum. Pathol. 27 (1996) 282-289
68. Brys M., Semczuk A., Rechberger T., and Krajewska W.M. Expression of erbB-1 and erbB-2 genes in normal and pathological human endometrium. Oncol. Rep. 18 (2007) 261-265
69. Khalifa M.A., Mannel R.S., Haraway S.D., Walker J., and Min K.W. Expression of EGFR, HER2/neu, p53 and PCNA in endometrioid, serous papillary, and clear cell endometrial carcinomas. Gynecol. Oncol. 53 (1994) 84-92
70. Reinartz J.J., George G., Lindren B.R., and Neihas G.A. Expression of p53, transforming growth factor α, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival. Hum. Pathol. 25 (1994) 1075-1083
71. Grushko T.A., Filiaci V.L., Mundt A.J., Riddersrale K., Olopade O.I., and Fleming G.F. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol. Oncol. 108 (2008) 3-9
72. Moy B., and Goss P.E. Lapatinib associated toxicity and practical management recommendations. Oncologist 12 (2007) 756-765
73. Konecny G.E., Venkatesan N., Yan G., Dering J., Ginther C., Finn R., et al. Activity of lapatanib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br. J. Cancer 98 (2008) 1076-1084
74. Cohen M.H., Williams G.A., Sridhara R., Chen G., McGuinn W.E., and Morse D. United States Food and Drug Administration Approval summary: fefitinig (ZD 1839) tablets. Clin. Cancer Res. 10 (2004) 1212-1218
75. Leslie K.K., Laidler L., Albitar L., et al. Tyrosine kinase inhibitors in endometrial cancer. Int. J. Gynecol. Cancer 15 (2005) 409-411
76. Jasa K.V., Fyles A Elit L., Hoskins P.J., Biagi J., Dubuc-Lissoir J., et al. Phase II study of erlotinib (OSI 774) in women with recurrent or metastatic endometrial cancer. J. Clin. Oncol. 22 (2004) 5019
77. Oza A.M., Eisenhauer E.A., Elit L., Cutz J.C., Sakurada A., Tsao M.S., et al. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J. Clin. Oncol. 26 (2008) 4319-4325
78. Slomovitz B.M., Broaddus R.R., Schmandt R., Wu W., Oh J.C., Ramondetta L., et al. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma. Gynecol. Oncol. 95 (2004) 32-36
79. Slomovitz B.M., Ramondetta L., Johnston T., Lu K.H., Broaddus R.R., Muller P., et al. A phase I study of imatinib mesylate and paclitaxel in patients with advanced or recurrent uterine papillary serous carcinoma. J. Clin. Oncol. 25 (2007) p16025
80. Albitar L., Carter M.B., Davies S., and Leslie K.K. Consequences of the loss of p53, RB1, and PTEN: Relationship to gefitinib resistance in endometrial cancer. Gynecol. Oncol. 106 (2007) 94-104
81. Villella J.A., Cohen S., Smith D.H., Hibshoosh H., and Hershman D. HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. Int. J. Gynecol. Cancer 16 (2006) 1897-1902
82. Jewell E., Secord A.A., Brotherton T., and Berchuck A. Trastuzumab in the treatment of metastatic endometrial cancer. Int. J. Gynecol. Cancer 16 (2006) 1370-1373
83. Goff B.A. Uterine papillary serous carcinoma: what have we learned over the past quarter century?. Gynecol. Oncol. 98 (2005) 341-343
84. Podratz K.C., and Mariani A. Uterine papillary serous carcinomas: the exigency for clinical trials. Gynecol. Oncol. 91 (2003) 461-462
85. Santin A.D., Zhan F., Cane S., Bellone S., Palmieri M., Thomas M., et al. Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. Br. J. Cancer 92 (2005) 1561-1573
86. Santin A.D., Bellone S., Marizzoni M., Palmieri M., Siegel E.R., McKenney J.K., et al. Overexpression of claudin-3 and claudin-4 receptors in uterine serous papillary carcinoma: novel targets for a type-specific therapy using Clostridium perfringes enterotoxin (CPE0. Cancer 109 (2007) 1312-1322
87. Weyer D, Funahashi T, Tanaka S, et al. Hypoadiponectiemia in obesity and Type 2 diabetes: close association with insulin resistance and hyperinsuliemia. J Clin Endocrinol Metab 201;86:1930-5.
88. Soliman P.T., Wu D., Tortolero-Luna G., Schmeler K.M., Slomovitz B.M., Bray M.S., et al. Association between adiponectin, insulin resistance and endometrial cancer. Cancer 106 (2006) 2376-2381
89. Evans J.M., Donnelly L.A., Emslie-Smith A.M., Alessi D.R., and Morris A.D. Metformin and reduced risk of cancer in diabetic patients. BMJ 330 7503 (2005) 1304-1305
90. Bowker S.L., Majumdar S.R., Veugelers P., and Johnson J.A. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29 2 (2006) 254-258
91. Cantrell L.A., Zhou C., Mendivil A., Gehrig P.A., and Bae-Jump V. Metformin is a potent inhibitor of endometrial cancer cell proliferation: implications for a novel treatment strategy. Gynecol. Oncol. 112 (2009) S79 Accepted Gynecol Oncol
92. Beltran P.J., Mitchell P., Chung Y.A., Cajeulis E., Lu J., Belmontes B., et al. AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Mol. Cancer Ther. 8 (2009) 1095-1105
93. Hewish M., Chau I., and Cunningham D. Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Pat. Anticancer Drug Discov. 4 (2009) 54-72
94. Mendivil A, Zhou C, Cantrell L, Gehrig PA, Bae-Jump V. AMG 479, a novel IGF-1R antibody, inhibits endometrial cancer proliferation through disruption of the P13K/Akt and MAPK pathways Proceedings of the American Association for Cancer Research. Abstract 2804.
95. Chon H.S., Hu W., and Kavanagh J.J. Targeted therapies in gynecologic cancers. Curr. Cancer Drug Targets 6 (2006) 333-336
96. Younes A., and Kadin M.E. Emerging applications of the tumor necrosis family of ligands and receptors in cancer therapy. J. Clin. Oncol. 21 (2003) 3526-3534
97. Leong S., Cohen R.B., Gustafson D.L., Langer C.J., Camidge D.R., Padavic K., et al. Mapatumumab, an antibody targeting TRAIL-R1 in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. J. Clin. Oncol. 27 (2009) 4413-4421
98. Hotte S.J., Hirte H.W., Chen E.X., Siu L.L., Le L.H., Corey A., et al. A phase I study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin. Cancer Res. 14 (2008) 3450-3455
99. Tolcher A.W., Mita M., Meropol N.J., von Mehren M., Patnaik A., Padavic K., et al. Phase I pharmacokinetic and biologic correlative study of mamatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor. J. Clin. Oncol. 25 (2007) 1390-1395